Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
NCT01543802 · Heidelberg University · PHASE2 · terminated · last registry update 2021-01-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow recruitment” | – | Registry record, Heidelberg University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-01-26Phase 3 first posted: Cogent Biosciences, Inc., CGT9486 + CGT9486 (NCT05208047)
- 2022-01-11Results posted on the registry: Graybug Vision, Drug: GB-102 + Aflibercept (NCT03953079)
- 2021-12-02Results posted on the registry: OHSU Knight Cancer Institute, Edicotinib (NCT03557970)
- 2021-12-02Also stopped (terminated): OHSU Knight Cancer Institute, Edicotinib (NCT03557970)
- 2021-11-04Also stopped (terminated): OHSU Knight Cancer Institute, Dasatinib + Idelalisib (NCT01620216)
- 2021-10-29Also stopped (withdrawn): BioGene Pharmaceutical Ltd., Linifanib + BIBW2992 (NCT03481842)
- 2021-10-28Also stopped (terminated): SCRI Development Innovations, LLC, Pazopanib + Doxil (NCT01035658)
- 2021-10-19Results posted on the registry: NYU Langone Health, Nivolumab + Cabiralizumab (NCT03599362)
- 2021-10-19Also stopped (terminated): NYU Langone Health, Nivolumab + Cabiralizumab (NCT03599362)
- 2021-10-06Also stopped (terminated): Michael Weichenthal, PTK787/ZK 222584 + Dacarbazine (NCT00615160)
- 2021-10-04Results posted on the registry: OHSU Knight Cancer Institute, Dasatinib + Idelalisib (NCT01620216)
- 2021-09-24Results posted on the registry: Eisai Inc., Lenvatinib + Everolimus (NCT02811861)
- 2021-09-22Also stopped (terminated): GWT-TUD GmbH, pazopanib or guideline conform chemotherapy (NCT03735758)
- 2021-09-20Results posted on the registry: M.D. Anderson Cancer Center, Pazopanib + Temsirolimus (NCT01392183)
- 2021-09-13Phase 3 first posted: AstraZeneca, savolitinib + durvalumab (NCT05043090)
- 2021-09-13Also stopped (terminated): M.D. Anderson Cancer Center, Crizotinib (Xalkori) + Pazopanib (NCT01548144)
- 2021-09-10Results posted on the registry: University of Michigan Rogel Cancer Center, Nivolumab + cabiralizumab (NCT03927105)
- 2021-09-08Also stopped (terminated): AIO-Studien-gGmbH, Nivolumab + Sunitinib (NCT02959554)
- 2021-08-31Results posted on the registry: Five Prime Therapeutics, Inc., FPA008 (NCT02471716)
- 2021-08-19Results posted on the registry: Daiichi Sankyo Co., Ltd., Quizartinib + Cytarabine (NCT02834390)
- 2021-07-15Results posted on the registry: Graybug Vision, GB-102 (NCT04085341)
- 2021-07-09Results posted on the registry: Daiichi Sankyo Co., Ltd., Dabigatran Etexilate Mesylate + Quizartinib (NCT04459585)
- 2021-06-30Results posted on the registry: University of Washington, Gene Expression Analysis + Genetic Variation Analysis (NCT02551718)
- 2021-06-16Results posted on the registry: Ludwig Institute for Cancer Research, Chimeric monoclonal antibody cG250 + Sunitinib malate (NCT00520533)
- 2021-06-07Results posted on the registry: Daiichi Sankyo, Pexidartinib (NCT04223635)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision